Navigation Links
Cepheid Reports Fourth Quarter And Full Year 2012 Results
Date:1/24/2013

SUNNYVALE, Calif., Jan. 24, 2013 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today reported revenue for the fourth quarter of 2012 of $92.4 million.  Net income was $5.6 million, or $0.08 per share, which compares to revenue of $80.1 million and net loss of $1.6 million, or $(0.03) per share, in the fourth quarter of 2011.  2011 fourth quarter results reflected a one-time, non-cash charge to cost of sales of $5.4 million, or $0.08 per share, associated with the termination of a patent license.

Excluding stock compensation expenses, impairment of intangible assets and licenses and amortization of acquired intangibles, non-GAAP net income for the fourth quarter of 2012 was $14.2 million, or $0.20 per share.  This compares to a non-GAAP net income of $9.4 million, or $0.14 per share, in the fourth quarter of 2011.

Fiscal 2012 OverviewFor the year ended December 31, 2012, Cepheid reported revenue of $331.2 million which compares to revenue of $277.6 million in 2011.  Net loss for the year was $20.0 million, or $(0.30) per share, which compares to net income of $2.6 million, or $0.04 per share, in 2011.  2012 full year net loss reflected a charge of $15.1 million, or $0.23 per share, associated with a litigation settlement.

Excluding stock compensation expenses, a litigation settlement charge, impairment of intangible assets and licenses, amortization of acquired intangibles and a tax benefit related to an intercompany intellectual property transaction, non-GAAP net income for the year was $21.8 million, or $0.31 per share.  This compares to a non-GAAP net income of $29.6 million, or $0.44 per share, for the full year 2011.

"2012 was a challenging year for Cepheid as we worked through growing pains associated with the scale-up of our manufacturing operations and adapted to the incremental variability associated with our HBDC program," said John Bishop, Cepheid's Chief Executive Officer.  "Despite these distractions, we were able to grow our clinical test revenue by 32%, including 25% growth in our commercial business."

Continued Bishop, "We are proud of our commitment to innovation, and our investment in R&D continues to be among the most aggressive in the industry.  As we move into 2013 and beyond, Cepheid is entering a pivotal period of Xpert test menu expansion with a number of high volume, high value tests that substantially extend our opportunities in new and existing markets.  We fully expect this product cycle to drive both market expansion and menu consolidation within accounts thereby benefiting continued, industry-leading revenue growth and improving profitability."

Operational Overview

  • Fourth quarter of 2012 Clinical sales of $82.2 million grew 19% from $68.9 million in the fourth quarter of 2011, and total fourth quarter of 2012 product sales of $89.7 million grew 17% from the same quarter a year ago.  For the year ended December 31, 2012, total Clinical sales of $286.3 million grew 21% from $236.0 million reported for 2011. 
  • By industry, product sales were, in millions:
  • Three Months Ended December 31,Full Year Ended December 31,20122011Change20122011ChangeClinical Systems

    $  13.4$  19.9-33%$
    52.8$
    58.6-10%Clinical Reagents

    68.849.040%233.5177.432%Total Clinical 82.268.919%286.3236.021%Non-Clinical

    7.58.0-6%35.229.519%Total Product Sales$  89.7$  76.917%$  321.5$  265.521%


  • By geography, product sales were, in millions:
  • Three Months Ended December 31,Full Year Ended December 31,20122011Change20122011ChangeNorth AmericaClinical

    $  54.4$  46.417%$  190.0$  167.913%Other

    6.07.2-17%29.025.016%Total North America60.453.613%219.0192.914%InternationalClinical

    27.822.524%96.368.141%Other

    1.50.890%6.24.538%Total International29.323.326%102.572.641%Total Product Sales$  89.7$  76.917%$  321.5$  265.521%


  • During the fourth quarter of 2012, Cepheid placed a total of 153 GeneXpert systems in its commercial Clinical business.  Additionally, the Company placed a total of 68 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.  For the year ended December 31, 2012, Cepheid placed a total of 523 GeneXpert systems in its commercial Clinical business and an additional 506 GeneXpert systems as part of its HBDC program.  As of December 31, 2012, a cumulative total of 3,835 GeneXpert systems have been placed worldwide.
  • Cash and cash equivalents were $95.8 million as of December 31, 2012.
  • DSO was 43 days.
  • Business OutlookFor the fiscal year ending December 31, 2013, the Company expects:

  • Total revenue to be in the range of $375 to $385 million;
  • Net income to range from a net loss of $(0.05) to net income of $0.01 per share; 
  • Non-GAAP net income in the range of $0.41 to $0.46 per share. 
  • Expected non-GAAP net income excludes approximately $29 million related to stock compensation expense and approximately $4 million related to the amortization of acquired intangibles.  The fully diluted share count for the year is expected to be approximately 72 million, except in the event of a GAAP loss where the share count would be approximately 67 million shares.

    The following table reconciles net income (loss) per share to the non-GAAP net income per share range:Guidance Range for YearEnding December 31, 2013Low HighNet Income (Loss) Per Share$ (0.05)$  0.01Stock Compensation Expense0.400.39Amortization of Purchased Intangible Assets0.060.06Non-GAAP Measure of Net Income Per Share$   0.41$  0.46Accessing Cepheid's Fourth Quarter and Full Year 2012 Results Conference CallThe Company will host a management presentation at 2 p.m. Pacific Time on Thursday, January 24, 2013, to discuss the results.  To access the live webcast, please visit Cepheid's website at http://ir.cepheid.com at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

    About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the Company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the Company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.

    Use of Non-GAAP MeasuresThe Company has supplemented its reported GAAP financial information with non-GAAP measures that do not include litigation settlement expenses, employee stock-based compensation expense, a non-cash charge associated with the termination of a patent license, impairment of intangible assets and licenses and amortization of purchased intangible assets.  The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with U.S. GAAP.
    The Company's management uses the non-GAAP information internally to evaluate its ongoing business, continuing operational performance and cash requirements, and believes these non-GAAP measures are useful to investors as they provide a basis for evaluating the Company's cash requirements and additional insight into the underlying operating results and the Company's ongoing performance in the ordinary course of its operations.

    These non-GAAP measures may be different from non-GAAP measures used by other companies.  In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.  The Company believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with its results of operations as determined in accordance with U.S. GAAP and that these measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures.

    As described above, the Company excludes the following items from one or more of its non-GAAP measures when applicable:

    Litigation Settlement Expenses. These expenses consist primarily of expenses related to the settlement of our previously outstanding litigation with Abaxis.  This allocation was determined in accordance with ASC 450, Accounting for Contingencies (formerly SFAS No. 5), and ASC 605-25 (formerly EITF 00-21) using the concepts of fair value based on the past and estimated future revenue streams related to the products covered by the patents previously under dispute.  Specifically, the amount recorded in the income statement as Litigation settlement in the year ended December 31, 2012 represents the fair value of the royalty paid on past revenue streams and the residual amount after allocating value to the future revenue streams.  The Company excluded this item as it believes it is non-recurring in nature, and does not have a direct impact on the operation of the Company's core business. 

    Employee Stock-based Compensation Expense. These expenses consist primarily of expenses for employee stock options and employee restricted stock under ASC 718 (formerly SFAS 123(R)).  The Company excludes employee stock-based compensation expenses from its non-GAAP measures primarily because they are non-cash expenses that the Company does not believe are reflective of ongoing operating results in the period incurred.  Further, as the Company applies ASC 718, it believes that it is useful to investors to understand the impact of the application of ASC 718 on its results of operations.

    Impairment of Intangible Assets and Licenses and Amortization of Purchased Intangible Assets.  The Company incurs amortization of purchased intangible assets in connection with acquisitions and incurs impairment of intangible assets and licenses.  The Company excludes these items because these expenses are not reflective of ongoing operating results in the period incurred.  These amounts arise from the Company's prior acquisitions and have no direct correlation to the operation of the Company's business.

    Tax Benefit Related to Intercompany Intellectual Property (IP) Transaction.  The Company excluded a tax benefit related to an intercompany IP transaction from its results for non-GAAP net loss for the year ended December 31, 2012.  The Company excluded this item as it believes it is non-recurring in nature, and does not have a direct impact on the operation of the Company's core business. 

    Forward-Looking StatementsThis press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to potential growth, future revenues and future net income/loss and profitability, including on a non-GAAP basis, and test menu expansion. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our ability to successfully complete and bring on line additional manufacturing lines; our success in increasing direct sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; variability in systems placements and reagent pull-through in the Company's HBDC program and the level of sales through that program; other unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.

    All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

    FINANCIAL TABLES FOLLOW  CEPHEID 

     

    CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)

     Three Months Ended December 31, Years Ended
    December 31, 2012201120122011Revenues:System sales

    $  14,101$  20,371$   55,447$  61,948Reagent and disposable sales

    75,55756,576266,101203,576Total product sales

    89,65876,947321,548265,524Other revenues

    2,7753,1679,66412,051Total revenues 

    92,43380,114331,212277,575Costs and operating expenses:Cost of product sales 

    42,89638,632153,365122,840Collaboration profit sharing 

    1,4161,5827,1834,863Research and development

    17,29916,65071,67359,362Sales and marketing

    16,29414,49061,90750,691General and administrative

    9,47010,15343,29836,004Litigation settlement

    --15,110-Total costs and operating expenses 

    87,37581,507352,536273,760Income (loss) from operations 

    5,058(1,393)(21,324)3,815Other income (expense), net

    241(506)(4)(1,143)Income (loss) before income taxes

    5,299(1,899)(21,328)2,672Benefit from (provision for) income taxes

    3452501,285(45)Net income (loss)

    $
    5,644$  (1,649)$ (20,043)$
    2,627Basic net income (loss) per share 

    $
    .09$
    (0.03)$
    (0.30)$
    .04Diluted net income (loss) per share 

    $
    .08$
    (0.03)$
    (0.30)$
    .04Shares used in computing basic net income (loss) per share 

    66,37064,11365,81262,735Shares used in computing diluted net income (loss) per share 

    68,78764,11365,81266,750CEPHEID 

     

    CONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS(in thousands)

     December 31,
    2012December
    31, 2011ASSETSCurrent assets:Cash and cash equivalents

    $
    95,779$
    5,008Accounts receivable, net

    43,99935,375Inventory

    70,11462,239Prepaid expenses and other current assets 

    9,4485,245Total current assets

    219,340217,867Property and equipment, net

    54,83035,833Other non-current assets

    913730Intangible assets, net

    18,76713,795Goodwill

    37,69418,445Total assets

    $
    331,544$
    286,670LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable 

    $
    33,701$
    32,167Accrued compensation 

    16,54017,928Accrued royalties 

    7,9928,357Accrued and other liabilities 

    4,2353,086Current portion of deferred revenue

    9,5998,176Current portion of notes payable

    183-Total current liabilities 

    72,25069,714Long-term portion of deferred revenue

    1,1562,003Notes payable, less current portion

    1,685-Other liabilities

    8,9113,120Total liabilities

    84,00274,837Shareholders' equity:Common stock

    355,867324,211Additional paid-in capital 

    117,21793,144Accumulated other comprehensive income

    5633Accumulated deficit 

    (225,598)(205,555)Total shareholders' equity 

    247,542211,833Total liabilities and shareholders' equity 

    $
    331,544$
    286,670 CEPHEID 

     

    CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS(in thousands)

     Years Ended December 31,20122011Cash flows from operating activities:Net income (loss)

    $  (20,043)$
    2,627Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation and amortization of property and equipment

    13,44610,298Amortization of intangible assets 

    4,9656,523Amortization of terminated patent license and impairment of acquired intangible assets

    1,3995,372Stock-based compensation related to employees and consulting services rendered

    24,49619,768Changes in operating assets and liabilities:Accounts receivable 

    (6,443)(7,830)Inventory 

    (5,105)(23,982)Prepaid expenses and other current assets 

    (2,714)(237)Other non-current assets

    (172)(122)Accounts payable and other current liabilities 

    (5,740)11,365Accrued compensation 

    (1,736)5,334Deferred revenue 

    575(2,084)Net cash provided by operating activities 

    2,92827,032Cash flows from investing activities:Capital expenditures 

    (23,150)(18,922)Cash paid for intangible asset

    (2,140)-Payments for technology licenses 

    -(1,655)Cost of acquisitions, net

    (24,021)(296)Net cash used in investing activities 

    (49,311)(20,873)Cash flows from financing activities:Net proceeds from the issuance of common shares and exercise of stock options

    27,07935,857Proceeds from notes payable

    156-Principal payment of notes payable

    (72)(6,669)Net cash provided by financing activities 

    27,16329,188Effect of exchange rate change on cash

    (9)123Net increase (decrease) in cash and cash equivalents 

    (19,229)35,470Cash and cash equivalents at beginning of period 

    115,00879,538Cash and cash equivalents at end of period

    $   95,779$  115,008 CEPHEID  

    RECONCILIATION OF GAAP TO NON-GAAP MEASURES (UNAUDITED)(in thousands, except per share data)Three Months Ended
    December 31,Years Ended
    December 31,2012201120122011Cost of product sales$ 42,896$ 38,632$ 153,365$ 122,840  Stock compensation expense(808)(443)(3,037)(1,684)  Impairment of intangible assets and licenses(1,233)(5,372)(1,233)(5,372)  Amortization of purchased intangible assets(332)(347)(1,330)(1,383)Non-GAAP measure of cost of product sales$ 40,523$ 32,470$ 147,765$ 114,401Gross margin on product sales per GAAP52%50%52%54%Gross margin on product sales per Non-GAAP55%58%54%57%Operating expenses$ 43,063$ 41,293$ 176,878$ 146,057  Stock compensation expense(5,756)(4,806)(21,415)(18,084)  Impairment of intangible assets and licenses(328)-(328)-  Amortization of purchased intangible assets(376)(107)(1,452)(429)Non-GAAP measure of operating expenses$ 36,603$ 36,380$ 153,683$ 127,544Income (loss) from operations$   5,058$ (1,393)$ (21,324)$
    3,815  Stock compensation expense6,5645,24924,45219,768  Amortization of purchased intangible assets7084542,7821,812  Impairment of intangible assets and licenses1,5615,3721,5615,372  Litigation settlement--15,110-Non-GAAP measure of income from operations$ 13,891$   9,682$   22,581$   30,767Net income (loss)$   5,644$ (1,649)$ (20,043)$
    2,627  Stock compensation expense6,5645,24924,45219,768  Amortization of purchased intangible assets7084542,7821,812  Impairment of intangible assets and licenses, net of tax1,2885,3721,2885,372  Litigation settlement--15,110-  Tax benefit related to intercompany IP transaction--(1,815)-Non-GAAP measure of net income$ 14,204$   9,426$   21,774$   29,579Basic net income (loss) per share$
    .09$   (0.03)$
    (0.30)$
    .04  Stock compensation expense0.090.080.370.32  Amortization of purchased intangible assets0.010.010.040.03  Impairment of intangible assets and licenses, net of tax0.020.090.020.08  Litigation settlement--0.23-  Tax benefit related to intercompany IP transaction--(0.03)-Non-GAAP measure of net income per share$
    .21$
    .15$
    .33$
    .47Diluted net income (loss) per share$
    .08$   (0.03)$
    (0.30)$
    .04  Stock compensation expense0.090.080.350.29  Amortization of purchased intangible assets0.010.010.040.03  Impairment of intangible assets and licenses, net of tax0.020.080.020.08  Litigation settlement--0.23-  Tax benefit related to intercompany IP transaction--(0.03)-Non-GAAP measure of net income per share$
    .20$
    .14$
    .31$
    .44Shares used in computing basic net income (loss) per share66,37064,11365,81262,735Shares used in computing diluted net income (loss) per share68,78764,11365,81266,750  Impact of dilutive securities in periods of GAAP net loss and Non-GAAP net income5894,4803,888878Shares used in computing Non-GAAP diluted net income per share

    69,37668,59369,70067,628 

    CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

    Cepheid Corporate Communications

    Tel: (408) 400 8377

    communications@cepheid.com

    Jacquie Ross

    Cepheid Investor Relations

    Tel: (408) 400 8329

    investor.relations@cepheid.com
    '/>"/>

    SOURCE Cepheid
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Cepheid to Webcast Upcoming Financial Presentations
    2. Cepheid Announces Executive Vice President Emerging Markets
    3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
    8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
    10. Luminex Corporation Reports First Quarter 2012 Results
    11. Hospira Reports First-Quarter 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/8/2016)... , Feb. 8, 2016 Velano Vascular, a ... for hospitalized patients and their practitioners, announced today that ... funding. Velano will use the proceeds from this financing, ... completed in January 2015, to support the development and ... and pediatric populations. Philadelphia ...
    (Date:2/8/2016)... Calif. , Feb. 8, 2016  HemaFlo Therapeutics, Inc. ... (USPTO) has issued US Patent Number 9,119,880 covering the use ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ... --> Dale Peterson , PhD, HemaFlo,s founder, ... a powerful technology." --> Dale Peterson ...
    (Date:2/8/2016)... NORTHBROOK, Ill. , Feb. 8, 2016  Astellas Pharma ... today announced the promotion of James Robinson as ... the company,s operations in North and South America ... president, Astellas Pharma US, representing the commercial organization in ... assumed in 2013. Masao Yoshida , who ...
    Breaking Medicine Technology:
    (Date:2/8/2016)... , ... February 08, 2016 , ... Guruji Mahendra Kumar ... 10th and 11th, 2016 in honor of his birthday on February 10th. During ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries ...
    (Date:2/7/2016)... Metamora, Michigan (PRWEB) , ... February 07, 2016 ... ... pelvic organ prolapse with the latest techniques and the most minimally invasive approaches. ... pelvic organ prolapse, particularly after menopause. Other risk factors include surgery to the ...
    (Date:2/7/2016)... ... February 07, 2016 , ... ... has added Kybella® to his medical and surgical expertise. Technically known as deoxycholic ... injectable medication used as a non-surgical alternative for reduction of fat below the ...
    (Date:2/6/2016)... ... ... With the FCPX LUT: Summer pack from Pixel Film Studios, ... is a Lookup Table that contains a mathematical formula for modifying an image. The ... manipulating each pixel, LUT's can change each color range differently, it gives the user ...
    (Date:2/5/2016)... SARASOTA, Florida (PRWEB) , ... February 05, 2016 , ... ... an event he has completed every year since it started in 2003. This year, ... attracting the attention of fellow runners and NBA team the Miami Heat. , This ...
    Breaking Medicine News(10 mins):